Last reviewed · How we verify
Low dose Rosuvastatin
Low dose Rosuvastatin is a Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University. It is currently FDA-approved. Also known as: Rosuvastatin Calcium, Crestor.
At a glance
| Generic name | Low dose Rosuvastatin |
|---|---|
| Also known as | Rosuvastatin Calcium, Crestor |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) (NA)
- Comparison of High and Moderate Intensity Statins in Achieving the Target LDL-C Level After Acute Coronary Syndrome (NA)
- Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
- Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI (PHASE4)
- Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention (PHASE4)
- Polypill in Acute Coronary Syndrome (PHASE2)
- A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin. (PHASE1)
- VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose Rosuvastatin CI brief — competitive landscape report
- Low dose Rosuvastatin updates RSS · CI watch RSS
- Nanjing First Hospital, Nanjing Medical University portfolio CI
Frequently asked questions about Low dose Rosuvastatin
What is Low dose Rosuvastatin?
Low dose Rosuvastatin is a Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University.
Who makes Low dose Rosuvastatin?
Low dose Rosuvastatin is developed and marketed by Nanjing First Hospital, Nanjing Medical University (see full Nanjing First Hospital, Nanjing Medical University pipeline at /company/nanjing-first-hospital-nanjing-medical-university).
Is Low dose Rosuvastatin also known as anything else?
Low dose Rosuvastatin is also known as Rosuvastatin Calcium, Crestor.
What development phase is Low dose Rosuvastatin in?
Low dose Rosuvastatin is FDA-approved (marketed).
Related
- Manufacturer: Nanjing First Hospital, Nanjing Medical University — full pipeline
- Also known as: Rosuvastatin Calcium, Crestor
- Compare: Low dose Rosuvastatin vs similar drugs
- Pricing: Low dose Rosuvastatin cost, discount & access